n response to blistering criticism, Marathon Pharmaceuticals has delayed the launch of a decades-old drug that was approved  last week and is supposed to cost $89,000. In a statement, Marathon chief executive Jeff Aronin said the company is “temporarily pausing” the launch “so we can fully engage with patients, caregivers and other stakeholders who have expressed concerns about access.”

The move comes just hours after two lawmakers, including Senator Bernie Sanders (I-Vt.), sent a harshly worded letter, blasting Marathon for “unconscionable” pricing for the drug, which would be used to treat a rare form of muscular dystrophy. And beyond urging the drug maker to lower its $89,000 price, they demanded the company fork over a raft of information, including development expenses and profit projections.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

Recommended Stories

Sign up for our biotech newsletter, The Readout

A guide to what’s new in biotech — delivered straight to your inbox every weekday morning.